Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Healthcare Coverage
GLIADEL Wafer assigned new DRG designation
September 5th, 2004
Guilford Pharmaceuticals, Inc., (GLFD) announced that GLIADEL Wafer (polifeprosan 20 with carmustine implant), the company's proprietary brain cancer treatment, has been assigned to a new Diagnosis Related Group (DRG) by the Centers for Medicare and Medicaid Services (CMS). The new DRG, DRG 543, Implantation of Chemotherapeutic Agents or Acute Complex Central Nervous System Principal Diagnosis, will take effect on October 1, 2004 and is expected to improve access to GLIADEL Wafer by providing increased payment to hospitals that provide the product to Medicare beneficiaries. GLIADEL Wafer is approved for use in newly diagnosed patients with high-grade...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
